Early Mild Hypertrophic Cardiomyopathy May Still Carry Significant Cardiovascular Risk
Approximately 21% of patients with phenotypically mild hypertrophic cardiomyopathy (HCM) experienced major adverse cardiovascular events (MACE) during a mean follow-up of seven years, highlighting that even apparently mild disease requires careful long-term monitoring. In this prospective analysis of 2,500 patients from the Sarcomeric Human Cardiomyopathy Registry, 21% developed MACE, including […]